12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Everolimus: Additional Phase III data

Additional data from an open-label Phase III trial in 719 de novo liver transplant patients showed that everolimus plus reduced-exposure tacrolimus (3-5 ng/mL) non-significantly reduced the treatment failure rate defined as a composite of death, graft loss or treated biopsy-proven acute rejection at 24 months vs. standard-exposure tacrolimus (6-10 ng/mL) (10.3% vs. 12.5%, p=0.452). Everolimus plus reduced-exposure tacrolimus did significantly reduce the incidence of treated biopsy-proven acute rejection at 24 months vs. standard-exposure tacrolimus alone (6.1% vs. 13.3%, p=0.01). Furthermore, everolimus plus reduced-exposure tacrolimus significantly improved renal failure as measured by the mean difference in eGFR change at 24 months vs. standard-exposure tacrolimus...

Read the full 494 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >